Cardiac Imaging

While cardiac ultrasound is the widely used imaging modality for heart assessments, computed tomography (CT), magnetic resonance imaging (MRI) and nuclear imaging are also used and are often complimentary, each offering specific details about the heart other modalities cannot. For this reason the clinical question being asked often determines the imaging test that will be used.

Boston Scientific Farapoint pulsed field ablation (PFA) catheter

FDA approves Boston Scientific’s Farapoint PFA catheter

The newest addition to the company's Farapulse PFA Platform was specifically approved to perform cavotricuspid isthmus ablation. 

Mirvat Alasnag, MD, FACP, FACC, FSCAI, FSCCT, director of catheterization laboratory and research, King Fahd Armed Forces Hospital, Jeddah-Saudi Arabia, Ditrector of TCT Middle East, and member of Society of Cardiovascular CT (SCCT) Education Committee, explains how the society it translating its educational content into other languages to help a wider international audience of clinicians. SCCT is working to expand its international membership and this is a big part of that strategy.

SCCT expands CCTA education overseas

SCCT has made it a priority to help clinicians from all over the world learn more about CCTA as the modality continues to transform patient care. 

PET-CT imaging of 124-I evuzamitide and SPECT-CT imaging of 99mTc-p5+14 showed radiotracer uptake in both AL and ATTR amyloid throughout the myocardium. Emily B. Martin, Anne Kassira, Alan Stuckey, et al. A tale of two tracers - Amyloid imaging with investigational radiotracers iodine (124I) evuzamitide and 99mTc-p5+14 (AT-05). https://www.journalofnuclearcardiology.org/article/S1071-3581(25)00325-3/abstract.

Bayer expands into molecular imaging with cardiac amyloidosis tracer acquisitions

Bayer is acquiring two cardiac amyloidosis radiotracers from Attralus, one for PET and one for SPECT. The SPECT tracer is also a theranostic agent to both image and treat amyloidosis.

Sunil Rao, MD, MSCAI, director, interventional cardiology, cardiac catheterization laboratory, NYU Langone Heart, professor, Department of Medicine, the Leon H. Charney Division of Cardiology, NYU Grossman School of Medicine, explains the prevalence, trends and predictors of same day discharge after percutaneous coronary intervention (PCI) data for non-ST-elevation acute coronary syndrome (NSTE-ACS) in clinical practice from the NCDR-CathPCI Registry.

Same-day discharge after PCI for NSTE-ACS is on the rise

Sunil Rao, MD, told Cardiovascular Business that same-day discharge is still relatively rare for these patients, but it appears to be growing more common over time. The COVID-19 pandemic appears to have played a key role in the development of this trend.

RSNA seeking new editor for cardiothoracic imaging journal

RSNA is looking for a replacement for Suhny Abbara, MD, who is now the editor-in-chief of its flagship journal.

Mirvat Alasnag, MD, FACP, FACC, FSCAI, FSCCT, director of catheterization laboratory and research, King Fahd Armed Forces Hospital, Jeddah-Saudi Arabia, director of TCT Middle East, and member of Society of Cardiovascular CT (SCCT) Education Committee, outlines why coronary CT angiography (CCTA) imaging will likely be a paradigm shift in cardiology, and where the gaps remain to gather more clinical evidence.

CCTA continues to transform cardiac imaging, interventional cardiology

Mirvat Alasnag, MD, spoke to Cardiovascular Business about CCTA's growing influence in cardiology. 

Sarah-Jane James, CT, MRI, molecular imaging senior market analyst for Signify Research, explains key trends in imaging systems she saw at the Radiological Society of North America (RSNA) 2025 meeting.

Key trends in medical imaging systems at RSNA 2025

Sarah-Jane James, imaging market analyst for Signify Research, discusses key trends in the specialty that she saw at the Radiological Society of North America's annual meeting. 

AI healthcare doctor surgery procedure artificial intelligence

FDA clears next-generation platform for AI-enabled ECG evaluations

AccurECG 2.0 was designed to interpret a total of 13 different rhythm classifications, including atrial fibrillation, atrial flutter and ventricular tachycardia.